Literature DB >> 29560966

Medical cannabis in the treatment of cancer pain and spastic conditions and options of drug delivery in clinical practice.

Leos Landa1,2, Jan Jurica1,3, Jiri Sliva4, Monika Pechackova5, Regina Demlova1,3.   

Abstract

The use of cannabis for medical purposes has been recently legalised in many countries including the Czech Republic. As a result, there is increased interest on the part of physicians and patients in many aspects of its application. This mini review briefly covers the main active substances of the cannabis plant and mechanisms of action. It focuses on two conditions, cancer pain and spasticity in multiple sclerosis, where its effects are well-documented. A comprehensive overview of a few cannabis-based products and the basic pharmacokinetics of marijuana's constituents follows. The review concludes with an outline for preparing cannabis (dried inflorescence) containing drug dosage forms that can be produced in a hospital pharmacy.

Entities:  

Keywords:  THC; cancer; cannabinoids; cannabis; mechanism of action; multiple sclerosis; pain; spasms

Mesh:

Substances:

Year:  2018        PMID: 29560966     DOI: 10.5507/bp.2018.007

Source DB:  PubMed          Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub        ISSN: 1213-8118            Impact factor:   1.245


  3 in total

1.  Myorelaxant Effect of Transdermal Cannabidiol Application in Patients with TMD: A Randomized, Double-Blind Trial.

Authors:  Aleksandra Nitecka-Buchta; Anna Nowak-Wachol; Kacper Wachol; Karolina Walczyńska-Dragon; Paweł Olczyk; Olgierd Batoryna; Wojciech Kempa; Stefan Baron
Journal:  J Clin Med       Date:  2019-11-06       Impact factor: 4.241

2.  Galenic Preparations of Therapeutic Cannabis sativa Differ in Cannabinoids Concentration: A Quantitative Analysis of Variability and Possible Clinical Implications.

Authors:  Alessandra Bettiol; Niccolò Lombardi; Giada Crescioli; Valentina Maggini; Eugenia Gallo; Alessandro Mugelli; Fabio Firenzuoli; Roberto Baronti; Alfredo Vannacci
Journal:  Front Pharmacol       Date:  2019-01-17       Impact factor: 5.810

3.  Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review.

Authors:  Jerome Sarris; Justin Sinclair; Diana Karamacoska; Maggie Davidson; Joseph Firth
Journal:  BMC Psychiatry       Date:  2020-01-16       Impact factor: 3.630

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.